REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.PMID 42127535 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.PMID 42166701 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.PMID 42167105 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.PMID 42202843 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.PMID 42214243 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.PMID 42296979 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.PMID 42308688 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.PMID 42372745 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.PMID 42418739 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.PMID 42214392 · 2026-Jun-27 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.PMID 42218899 · 2026-Jun-27 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.PMID 42202479 · 2026-Jun-25 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.PMID 41424028 · 2026-Jun-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.PMID 41980234 · 2026-Jun-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.PMID 42217458 · 2026-Jun-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.PMID 42225112 · 2026-Jun-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.PMID 41911073 · 2026-Jun-18 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.PMID 41915772 · 2026-Jun-18 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| [177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.PMID 42142431 · 2026-Jun-18 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.PMID 41915435 · 2026-Jun-15 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.PMID 41770817 · 2026-Jun-11 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.PMID 41369677 · 2026-Jun-10 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.PMID 41758929 · 2026-Jun-04 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.PMID 41967349 · 2026-Jun-03 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.PMID 42019226 · 2026-Jun-03 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.PMID 41285272 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.PMID 41504634 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial.PMID 41711624 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.PMID 41837753 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.PMID 42060297 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.PMID 42295761 · 2026-Jun-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).PMID 41073155 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.PMID 41535566 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.PMID 41571045 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.PMID 41621752 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.PMID 41687718 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma.PMID 41688329 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.PMID 41690366 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.PMID 41720427 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.PMID 41739398 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.PMID 41896648 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.PMID 41990300 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.PMID 41996761 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.PMID 42000139 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).PMID 42107198 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.PMID 42108156 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).PMID 42308452 · 2026-Jun | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.PMID 42202319 · 2026-May-28 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.PMID 42168151 · 2026-May-22 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.PMID 41564372 · 2026-May-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |